LONDON Haleon on Tuesday announced that it had informed GSK along with Pfizer (NYSE: PFE) that it had rejected their request for indemnification in connection with U.S.-based lawsuits concerning the heartburn medicine Zantac.
More than 2,000 legal proceedings concerning Zantac are pending in the United States over allegations that Zantac contains carcinogens that are likely to cause cancer.
Related: After the spin-off, Pfizer will leave GSK’s consumer health business.
Zantac originally promoted by a predecessor of GSK and GSK, has been marketed by a variety of companies at various time periods and includes Pfizer, Boehringer Ingelheim and Sanofi (NASDAQ: SNY) in addition to many generic drug companies.
Haleon is spun off as an independent corporation in July, consists of the consumer health products that were once controlled through GSK along with Pfizer.
